v3.22.1
Condensed Consolidated Statements of Comprehensive Income / (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenues $ 20,605 $ 23,291
Cost of goods sold 6,410 6,238
Gross profit 14,195 17,053
Operating Expenses:    
General and administrative 25,317 26,161
Research and development 4,447 2,875
Gain on acquisition contingency (8,503) (51)
Asset impairment and abandonments 939 2,176
Transaction and integration expenses 916 322
Total operating expenses 23,116 31,483
Operating loss (8,921) (14,430)
Other (income) expense - net:    
Other (income) expense - net 28 (4)
Interest expense 252 0
Foreign exchange loss 353 545
Change in fair value of warrant liability (9,743) 0
Total other (income) expense - net (9,110) 541
Income (Loss) before income tax provision 189 (14,971)
Income tax provision 162 219
Net income (loss) from operations 27 (15,190)
Noncontrolling interests    
Net income applicable to noncontrolling interests 0 0
Net income (loss) applicable to Surgalign Holdings, Inc. 27 (15,190)
Other comprehensive income (loss)    
Unrealized foreign currency translation gain (109) (71)
Total other comprehensive income (loss) $ 136 $ (15,119)
Net loss from operations per share - basic (in dollars per share) $ 0.00 $ (0.15)
Net loss per share applicable to Surgalign Holdings, Inc.- basic (in dollars per share) 0.00 (0.15)
Net loss from operations per share - diluted (in dollars per share) 0.00 (0.15)
Net loss per share applicable to Surgalign Holdings, Inc.- diluted (in dollars per share) $ 0.00 $ (0.15)
Weighted average basic shares (in shares) 172,009,259 98,109,900
Weighted average diluted shares (in shares) 177,328,099 98,109,900

Source